Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · IEX Real-Time Price · USD
7.92
-0.04 (-0.50%)
Jul 22, 2024, 10:28 AM EDT - Market open
Outlook Therapeutics Employees
Outlook Therapeutics had 24 employees as of September 30, 2023. The number of employees increased by 7 or 41.18% compared to the previous year.
Employees
24
Change (1Y)
7
Growth (1Y)
41.18%
Revenue / Employee
n/a
Profits / Employee
-$6,630,544
Market Cap
184.90M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
EDAP TMS | 307 |
Coherus BioSciences | 306 |
Seres Therapeutics | 233 |
908 Devices | 230 |
Inhibrx | 172 |
OptimizeRx | 136 |
Biomea Fusion | 103 |
Fractyl Health | 94 |
OTLK News
- 14 days ago - Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD - GlobeNewsWire
- 5 weeks ago - Outlook Therapeutics(R) (NASDAQ: OTLK) to Participate Virtual Investor Closing Bell Series - Accesswire
- 5 weeks ago - Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference - GlobeNewsWire
- 6 weeks ago - Outlook Therapeutics(R) (NASDAQ:OTLK) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team - Accesswire
- 7 weeks ago - Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD - GlobeNewsWire
- 2 months ago - Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD - GlobeNewsWire
- 2 months ago - Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast - GlobeNewsWire